Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) announced its quarterly earnings results on Tuesday. The company reported $1.69 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $1.02, FiscalAI reports. The firm had revenue of $5.95 billion for the quarter, compared to analyst estimates of $4.80 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 3.72% and a return on equity of 7.42%.

Fresenius Medical Care AG & Co. KGaA Trading Up 0.8%

FMS opened at $24.57 on Tuesday. The firm’s fifty day moving average is $23.34 and its two-hundred day moving average is $24.48. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.00 and a current ratio of 1.36. The firm has a market cap of $14.24 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 0.77 and a beta of 0.90. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.94 and a twelve month high of $30.46.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently bought and sold shares of FMS. CIBC Private Wealth Group LLC raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% during the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after acquiring an additional 1,103 shares during the period. Arax Advisory Partners increased its holdings in Fresenius Medical Care AG & Co. KGaA by 121.6% during the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares in the last quarter. Kestra Advisory Services LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the 4th quarter valued at about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the fourth quarter valued at about $58,000. Finally, Group One Trading LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA in the third quarter valued at about $74,000. 8.37% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

FMS has been the topic of several research analyst reports. The Goldman Sachs Group cut shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 20th. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, January 27th. Truist Financial set a $28.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Erste Group Bank cut Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Finally, Wall Street Zen upgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 20th. Five analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA currently has a consensus rating of “Reduce” and an average price target of $28.00.

Fresenius Medical Care AG & Co. KGaA Company Profile

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.